Chief development officer at Spinogenix.
Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD
August 1st 2025The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 minutes]
2 Commerce Drive
Cranbury, NJ 08512